National Psoriasis Foundation recommends COVID-19 vaccine in pandemic guidelines

摘要

The National Psoriasis Foundation's COVID-19 task force has updated its guidelines for managing psori-atic disease during the pandemic. The guidelines, published in Journal of the American Academy of Dermatology, were developed by a task force of 18 dermatology, rheumatology, epidemiology, infectious diseases and critical care physicians. The task force first issued 22 guidelines in September 2020 and reaffirmed those points, while adding five new recommendations, leading with a strong suggestion that anyone who has access to a vaccine should receive one. "We have put out 27 recommendations related to how psoriasis and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination) and what they should do if they develop COVID-19," Healio Psoriatic Disease Chief Medical Editor Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine and co-chair of the NPF COVID-19 task force, told Healio. "Most critically, we recommend that patients with psoriatic disease, should receive an mRNA-based COVID-19 vaccine as soon as it becomes available to them and that patients who are to receive a mRNA-based COVID-19 vaccine continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis during the vaccine period."